Navigation Links
Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009
Date:3/31/2009

BELGRADE, SERBIA, March 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - The "Best Technological Innovation Award" is a most coveted, prestigious award, and is announced annually by the Serbian Ministry of Science and Technological Development. Submitted with the award application, HTDS included extremely encouraging results from the preliminary trial of their Ribavirin product, confirming its combative effective against glial scarring.

HTDS Chief Scientist, Dr. Sanja Pekovic was elected as an expert to represent Serbia in the COST (European Cooperation In The Field of Scientific And Technical Research) Action B30: Neural Regeneration and Plasticity. Meetings are scheduled twice a year.

Recently, HTDS - IBISS GROUP competed for the European Collaborative Project (FP7). Dr. Pekovic said "We are delighted to have successfully passed the first level of selection. HTDS is looking forward to another great year." Final results will be released sometime in 2009.

The company will provide further details as they become available.

Safe Harbor

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Australian clinical trials threatened: Jobs and patient access to new treatments at stake
2. US Market for Minimally Invasive Treatment of Varicose Veins to Rise to More than $215 Million by 2013
3. Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software
4. Ear Health News: Natural Treatments to Ease Tinnitus Intensity
5. Arthritis Treatments and Joint Pain Relief Ideas Featured on Newly Launched Arthritis Today Web Site
6. New Device Treats Common Heart Rhythm Disorder
7. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
8. Microsurgery May Cut Swelling After Breast Cancer Treatment
9. Treatment Target for Herpes Pinpointed
10. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
11. Individualized stroke treatment available for patients, though underutilized
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a definitive agreement ... laboratory service centers across the country. Launched in April of 2015, Apifiny is the ... prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... , Feb. 10, 2016 Mast ... developing novel, clinical-stage therapies for sickle cell disease and ... public offering of 29,090,910 units at a price to ... of one share of the Company,s common stock and ... common stock at an exercise price of $0.42 per ...
(Date:2/10/2016)... , Feb. 10, 2016 ALSP, Inc. announced ... MD as Consultant for Medical Affairs in preparation for its ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased to ... look forward to working with an individual of such practical ... look forward to drawing deeply on his broad experience and ...
Breaking Medicine Technology: